| Patent(s) and the Corresponding Patented Drug(s) |
Top |
| World Intellectual Property Organization (WIPO) |
| Patent ID |
WO2006079637 |
| Title |
Heterocyclic Tetracyclic Tetrahydrofuran Derivatives As 5Ht2 Inhibitors In The Treatment of Cns Disorders. |
| Abstract |
This invention concerns novel substituted heterocyclic tetracyclic tetrahydrofuran derivat ives with binding affinities towards serotonin receptors, in particular 5-HT2A and 5- HT2C receptors, and towards dopamine receptors, in particular dopamine D2 receptors and with norepinephrine reuptake inhibition properties, pharmaceutical compositions comprising the compounds according to the invention, the use thereof as a medicine, in particular for the prevention and/or treatment of a range of psychiatric and neurological disorders, in particular certain psychotic, cardiovascular and gastrokinetic disorders and processes for their production. The compounds according to the invention can be represented by general Formula (I) , and comprises also the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the N-oxide form thereof and prodrugs thereof, wherein all substituents are defined as in Claim 1. |
| Applicant(s) |
Janssen Pharmaceutica Nv |
| Representative Drug(s) |
D0M1RM |
Drug Info
|
N.A. |
[1] |
| Patent ID |
WO2012176066 |
| Title |
Deuterated 1-Piperazino-3-Phenyl Indanes for Treatment of Schizophrenia. |
| Abstract |
The present invention relates to deuterated 1-piperazino-3-phenyl-indanes and salts thereof with activity at dopamine receptors D1 and D2 as well as the 5HT2 receptors in the central nervous system, to medicaments comprising such compounds as active ingredients, to the use of such compounds in the treatment of diseases in the central nervous system, and to methods of treatment comprising administration of such compounds. |
| Applicant(s) |
H. Lundbeck A / S |
| Patent ID |
WO1999052927 |
| Title |
Non-Endogenous, Constitutively Activated Human Serotonin Receptors and Small Molecule Modulators Thereof. |
| Abstract |
Disclosed herein are non-endogenous, constitutively activated forms of the human 5-HT2A and human 5-HT2C receptors and uses of such receptors to screen candidate compounds. Further disclosed herein are candidate compounds identified by the screening method which act at the 5HT2A receptors. Yet further disclosed is a new class of compounds which act at the 5HT2A receptors. |
| Applicant(s) |
Arena Pharmaceuticals, Inc |
| United States Patent and Trademark Office (USPTO) |
| Patent ID |
US20110207744 |
| Title |
Method for Treating Cognitive Deficits. |
| Applicant(s) |
H. Lundbeck A / S |
